Shares of Artivion (AORT) tumbled 6.64% in after-hours trading on Monday, following the company's disappointing fourth quarter 2024 earnings report. The medical device maker missed Wall Street's expectations on both the top and bottom lines.
For the quarter, Artivion reported adjusted earnings per share of $0, falling short of analysts' consensus estimate of $0.06 per share. The company also fell short on revenue, generating $97.31 million compared to the $100.82 million projected by analysts.
The weaker-than-expected results weighed on investor sentiment, with Artivion's stock shedding over 6% of its value in extended trading hours after the earnings miss. Investors appeared disappointed by the company's lackluster performance to close out fiscal 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。